CM
Crestline Management’s Syndax Pharmaceuticals SNDX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-713,205
| Closed | -$9.43M | – | 546 |
|
|
2024
Q4 | $9.43M | Buy |
713,205
+284,667
| +66% | +$3.76M | 0.31% | 52 |
|
|
2024
Q3 | $8.25M | Buy |
428,538
+285,258
| +199% | +$5.49M | 0.43% | 57 |
|
|
2024
Q2 | $2.94M | Buy |
143,280
+39,570
| +38% | +$812K | 0.23% | 114 |
|
|
2024
Q1 | $2.47M | Buy |
103,710
+3,061
| +3% | +$72.9K | 0.22% | 120 |
|
|
2023
Q4 | $2.18M | Sell |
100,649
-33,815
| -25% | -$731K | 0.19% | 126 |
|
|
2023
Q3 | $1.95M | Buy |
134,464
+22,000
| +20% | +$319K | 0.23% | 109 |
|
|
2023
Q2 | $2.35M | Buy |
112,464
+17,255
| +18% | +$361K | 0.25% | 105 |
|
|
2023
Q1 | $2.01M | Buy |
95,209
+31,002
| +48% | +$655K | 0.24% | 97 |
|
|
2022
Q4 | $1.63M | Buy |
64,207
+656
| +1% | +$16.7K | 0.24% | 79 |
|
|
2022
Q3 | $1.53M | Buy |
63,551
+3,000
| +5% | +$72.1K | 0.21% | 92 |
|
|
2022
Q2 | $1.17M | Sell |
60,551
-2,965
| -5% | -$57K | 0.15% | 110 |
|
|
2022
Q1 | $1.1M | Buy |
+63,516
| New | +$1.1M | 0.13% | 130 |
|
|
2018
Q3 | – | Sell |
-35,027
| Closed | -$246K | – | 226 |
|
|
2018
Q2 | $246K | Sell |
35,027
-1,687
| -5% | -$11.8K | 0.03% | 228 |
|
|
2018
Q1 | $522K | Sell |
36,714
-46,425
| -56% | -$660K | 0.06% | 192 |
|
|
2017
Q4 | $728K | Buy |
83,139
+29,607
| +55% | +$259K | 0.07% | 127 |
|
|
2017
Q3 | $626K | Sell |
53,532
-1,836
| -3% | -$21.5K | 0.09% | 117 |
|
|
2017
Q2 | $773K | Buy |
+55,368
| New | +$773K | 0.1% | 98 |
|